Utility of Amino-Terminal Pro–Brain Natriuretic Peptide Testing for Prediction of 1-Year Mortality in Patients With Dyspnea Treated in the Emergency Department

Open Access
Publisher Website
Google Scholar
Abstract
B-type natriuretic peptide testing is useful for the diagnostic evaluation of patients with dyspnea and suspected acute destabilized congestive heart failure (CHF).1-3 Including both the B-type natriuretic peptide and its profragment, amino-terminal pro–brain natriuretic peptide (NT-proBNP), this class of cardiac biomarkers is useful not only for diagnosis or exclusion of CHF but also for stratification of long-term risk of mortality in community-based populations without CHF4 and those with chronic CHF.5-9 It is also useful to predict prognosis in individuals with non-CHF states, such as coronary artery disease,10-19 pulmonary embolism (PE),20,21 and critical illness,22 and following cardiac transplantation.23 However, the role of the B-type natriuretic peptides for defining the longer-term prognosis of patients who present with dyspnea to the emergency department (ED)—the most common indication for B-type natriuretic peptide measurement—remains undefined.

This publication has 26 references indexed in Scilit: